Skip to Content
Søg Menu
EHA 2026 I

The European Hematology Association

EHA 2026

Florian Simon

EHA 2026: Acalabrutinib Shows Durable Responses in Frail and Elderly Patients with CLL

/ Florian Simon
EHA26CLL Play the Video

EHA 2026: Combination Therapy Provides Durable QoL and Physical Function Benefits in Treatment-Naïve CLL

/ Jan Andreasen
EHA26CLL
Panagiotis Baliakas

EHA 2026: Germline Testing Beyond Family History in AML and MDS

/ Panagiotis Baliakas
EHA26 Play the Video
Mika Kontro

EHA 2026: Novel Cell Therapy Approaches in AML

/ Mika Kontro
EHA26AML Play the Video
Caroline Arvé

EHA 2026: MRD Predicts Post-Transplant Relapse in High-Risk MDS and AML

/ Caroline Arvé
EHA26AML Play the Video
Astrid Hundeboell Torpe

EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma

/ Astrid Hundebøll Torpe
EHA26Myelomatose Play the Video
Dr. Lei Fan

EHA 2026: LB2501 Advances In Vivo CAR-T with Single-Infusion Treatment

/ Lei Fan
CAR-TEHA26Lymfom Play the Video
Maren Poulsgaard Jørgensen

EHA 2026: Increased Risk of Psychotropic Drug Use Observed in Patients with Mastocytosis

/ Maren Poulsgaard Jørgensen
EHA26 Play the Video
Astrid Hundeboell Torpe

EHA 2026: Low-Dose Venetoclax Demonstrates Durable Responses in Relapsed/Refractory t(11;14) Multiple Myeloma

/ Astrid Hundebøll Torpe
EHA26Myelomatose Play the Video
Andreas Glenthøj

EHA 2026: Advances in Sickle Cell Disease and Beta-Thalassemia

/ Andreas Glenthøj
EHA26Seglcelleanæmi Play the Video
Stephan Stilgenbauer

EHA 2026: Tacabrutideg Shows High Response Rates and Durable Outcomes in High-Risk Relapsed/Refractory CLL

/ Stephan Stilgenbauer
EHA26CLL Play the Video
Johanne Skovgaard Schovsbo

EHA 2026: Comparable Outcomes with Reduced-Dose Treosulfan

/ Johanne Skovgaard Schovsbo
EHA26 Play the Video
Binod Dhakal

EHA 2026: CB-011 Shows High Response Rates in Relapsed/Refractory Myeloma

/ Binod Dhakal
EHA26Myelomatose Play the Video
Lea Löffler

EHA 2026: Thromboinflammatory Markers Are Elevated Years Before MPN Diagnosis and May Reflect Risk of Progression

/ Lea Maria Elisabeth Löffler
EHA26 Play the Video
Binod Dhakal

EHA 2026: Deep And Durable Responses With AZD0120 In Relapsed/Refractory Multiple Myeloma

/ Binod Dhakal
EHA26Myelomatose Play the Video
Cecilia Langenskiöld

EHA 2026: Early Curative Treatment in Pediatric Sickle Cell Disease and Thalassemia

/ Cecilia Langenskiöld
EHA26Seglcelleanæmi Play the Video
Frida Bugge Askeland

EHA 2026: MRD-Negative Responses And Outcomes After VRD Induction And Transplant In Newly Diagnosed Multiple Myeloma

/ Frida Bugge Askeland
EHA26Myelomatose Play the Video

Patients Take Center Stage at EHA 2026

/ Jan Andreasen
EHA26
Sigrun Thorsteinsdottir

EHA 2026: Circulating Tumor Plasma Cells Predict Progression in Smoldering Myeloma

/ Sigrun Thorsteinsdottir
EHA26Myelomatose Play the Video

EHA 2025

Sigrun Thorsteinsdottir

EHA 2025: Behandling af myelomatose i dansk perspektiv

/ Sigrun Thorsteinsdottir
EHA25Myelomatose Play the Video
Sirpa Leppä

EHA 2025: Biomarkers as a Guide in Lymphoma Treatment

/ Sirpa Leppä
EHA25Lymfom Play the Video
Daniel Tuyet Kristensen

EHA 2025: Gradvis forbedring af eksisterende AML-behandlinger

/ Daniel Kristensen
EHA25AML Play the Video
Tarec Christoffer El-galaly

Manglende evidens for behandling af ældre

/ Tarec Christoffer El-Galaly
EHA25 Play the Video
Fredrik Hellem Schjesvold

EHA 2025: Real-World Insights on Belantamab Mafodotin in RRMM

/ Fredrik Schjesvold
EHA25Myelomatose Play the Video
Malin Rasmussen

EHA 2025: Radiotherapy in FL Linked to Low Relapse Rates

/ Malin Rasmussen
EHA25Lymfom Play the Video
Hent flere

EHA 2024

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ Sofie Pohl
EHA24Myelomatose

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
EHA24CLL
Hent flere

EHA 2023

Carsten Niemann

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

/ Carsten Utoft Niemann
EHA23CLL Play the Video

Potentiel kurativ genterapi af seglcellesygdom og β-talassæmi i klinisk perspektiv

/ Nina Toft / Jan Andreasen
SeglcelleanæmiThalassæmi

EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy 

/ Jan Andreasen / Amanda Feldballe Bernholm
EHA25
Anna Sureda Balari

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

/ Anna Sureda Balari
EHA23Lymfom Play the Video
Mark Levis

Gilteritinib for Patients with Newly Diagnosed AML

/ Mark Levis
EHA23Ernæring Play the Video
Arnon Kater

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Arnon Kater
EHA23CLL Play the Video
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video
Ryan Jacobs

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

/ Ryan Jacobs
EHA23Lymfom Play the Video
Barbara Eichhorst

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Barbara Eichhorst
EHA23CLL Play the Video
Eva Futtrup Maksten

Risk of Dementia in Older Patients Treated with Chemotherapy for Lymphoma

/ Eva Futtrup Maksten
EHA23LymfomDemens Play the Video

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose
Alan Z. Skarbnik

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

/ Alan Z. Skarbnik
EHA23CLL Play the Video
Hent flere

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
B-celle lymfomLymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

/ Hæmatologi / Carl Sandén

EHA 2025: Overcoming Venetoclax Resistance

/ Hæmatologi / Justinas Daraskevicius

EHA 2025: Nordic AML Group Explores Optimized Regimen for AML Patients

/ Hæmatologi / Anne Louise Tølbøll Sørensen

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Hæmatologi / Nikolaj Juul Nitschke

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Hæmatologi / Mark Levis
Se oversigt

CLL

EHA 2025: First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL

/ Hæmatologi / Lydia Scarfò

EHA 2025: Durable Undetectable MRD Responses with Acalabrutinib in CLL

/ Hæmatologi / Paolo Ghia

EHA 2025: Sonrotoclax + Zanubrutinib Show Durable Responses in R/R CLL/SLL

/ Hæmatologi / Chan Cheah

EHA 2025: Zanubrutinib Effective as First-Line CLL/SLL Therapy Regardless of del(17p)

/ Hæmatologi / Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Hæmatologi / Paolo Ghia
Se oversigt

Lymfom

Several Options for Frontline Treatment of MCL

/ Hæmatologi / Mats Jerkeman

EHA 2025: Signs of Functional Cure for MCL in 25 Years Nordic Follow-Up Study

/ Hæmatologi / Mats Jerkeman

Opsigtvækkende fremskridt på EHA for behandling af lymfom

/ Hæmatologi / Tarec Christoffer El-Galaly

More Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Can Participate in Clinical Studies

/ Hæmatologi / Jelena Jelicic

Presidential Symposium: Unmet Needs in the Lymphoma Field

/ Hæmatologi / Ari M. Melnick
Se oversigt

Myelomatose

EHA 2025: TG01 Shows Promise in KRAS-Mutated Myeloma

/ Hæmatologi / Hanne Norseth

EHA 2025: Impact of Treating MRD Relapse Post 1L in Multiple Myeloma

/ Hæmatologi / Frida Bugge Askeland

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hæmatologi / Hanne Norseth

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Hæmatologi / Frida Bugge Askeland

Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

/ Hæmatologi / Elin Forsgren
Se oversigt

Abstracts fra EHA 2022

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ Hæmatologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ Hæmatologi / BestPractice Nordic

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
B-celle lymfomLymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Daniel Kristensen

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

/ Daniel Kristensen
EHA22AML Play the Video
Agoston Gyula Szabo

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Agoston Gyula Szabo
EHA22Myelomatose Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

Mere fra EHA 2021

Significant improvements in OS and RFS for older patients with AML

/ Farhad Ravandi
EHA21AML Play the Video

Iberdomide show promising efficacy in heavily pretreated patients with Relapsed/Refractory Multiple Myeloma

/ Sagar Lonial
EHA21Myelomatose Play the Video

EHA-ESMO Clinical Practice Guidelines for Multiple Myeloma

/ Fredrik Schjesvold
EHA21Myelomatose Play the Video

Potential to become the best treatment for multiple myeloma in history

/ Thierry Facon
EHA21Myelomatose Play the Video

New bispecific antibody with promising efficacy and safety profil for patients with relapsed/refractory Multiple Myeloma

/ Amrita Y. Krishnan
EHA21Myelomatose Play the Video

Azacitidin tolereredes generelt godt af ældre patienter med AML

/ BestPractice Nordic
AlderdomEHA21AML
Læs mere

First-in-human study of teclistamab for relapsed/refractory Multiple Myeloma

/ Niels van de Donk
EHA21Myelomatose Play the Video

Early responses for BCMA-directed CAR-T cell therapy in progressive MM after 1-3 prior lines of therapy

/ Mounzer Agha
EHA21Myelomatose Play the Video

CAR-T-celleterapi giver tidligt og dyb respons ved myelomatose

/ BestPractice Nordic
CAR-TEHA21MyelomatoseT-celler
Back to top